On March 18, the 21st China International Laboratory Medicine and Blood Transfusion Instruments and Reagents Expo (CACLP) successfully concluded at the Chongqing International Expo Center!
This year at CACLP, HymonBio showcased a series of products for early detection of genes for multiple cancers such as colorectal cancer, gastric cancer, and bladder cancer. The booth was very popular and there was an endless stream of visitors. Everyone showed great interest in HymonBio products and reached an intention to cooperate.
At the exhibition site, Ms. Zhou Lei, general manager of Shanghai Jierui Bioengineering Co., Ltd., Dr. Zhao Baihui, chairman and general manager of Shanghai Berger Medical Technology Co., Ltd., and Zeng Minxia, R&D director of Zhuhai Livzon Reagent Co., Ltd. came to visit. HymonBio CEO Dr. Tammy Tan conducted in-depth exchanges and business negotiations with various partners.
The three-day 2024 CACLP has concluded successfully. HymonBio would like to express its sincere gratitude to all visiting customers, experts and scholars for their continued trust and support.
HymonBio will continue to develop advanced diagnostic reagents in the fields of early tumor screening and infectious diseases, continue producing high-quality products with internationally advanced standards, and assist the development and application of clinical molecular diagnostic technology.
Post time: Mar-18-2024